AC Immune Third Quarter 2026 Financial and Corporate Update

AC Immune reported positive clinical progress in Q3 2026, with its lead Parkinson's disease candidate ACI-7104 receiving FDA Fast Track designation and showing positive safety and immunogenicity results through week-100 in the Phase 2 VacSYn trial. The company also reported positive Phase 1 results for NLRP3 inhibitor ACI-19764 and nominated a lead candidate in its small molecule alpha-synuclein program. With CHF 73.9 million in cash resources, the company has runway into Q1 2028.